Search

Your search keyword '"Morelli, F"' showing total 720 results
Start Over Author "Morelli, F"
720 results on '"Morelli, F"'

102. Chronic administration of bumetanide upregulates calbindin D28k mRNA and protein abundandance in rat distal convoluted tubules. Nephron Physiol

Author

RIZZO M., METAFORA S., MORELLI F., RUSSO F., CIANI, FRANCESCA, CAPASSO G., Rizzo, M., Metafora, S., Morelli, F., Russo, F., Ciani, Francesca, and Capasso, G.

Subjects
rat DCT, Calbindin-D28K, bumetanide
Abstract

BACKGROUND/AIMS: Calbindin D28k has been reported to be involved in transcellular calcium transport along the rat distal convoluted tubule (DCT). It has also been shown that administration of bumetanide is associated with hypercalciuria. The experiments reported here were designed to verify whether chronic infusion of this diuretic affects the gene expression and protein abundance of calbindin D28k along rat kidney DCT. METHODS: Bumetanide was subcutaneously infused by an osmotic minipump for 7 days at a rate of 1.5 mg x h(-1) x kg(-1). cDNA was synthesized from total RNA extracted from DCT microdissected from collagenase-treated kidneys. RESULTS: Calbindin D28k mRNA abundance, quantified by competitive PCR, was found to be 13.7 +/- 1.9 amol x ng(-1) total RNA in DCT of control rats (n = 4) as compared to 24.2 +/- 2.4 amol x ng(-1) total RNA in DCT of bumetanide- treated rats (n = 5) (p < 0.01). This effect was associated with a 52% increase (p < 0.005) in calbindin D28k protein abundance, as detected by Western blot performed on tissue slices from renal cortex (n = 4). CONCLUSION: These data not only demonstrate that bumetanide upregulates the mRNA and protein abundance of calbindin D28k in rat DCT, but also suggest that DCT calcium reabsorption is increased following the administration of this loop diuretic.

Published
2004

104. Low-impact chemical weed control techniques in UNESCO World Heritage Sites of Cuba

Author

Hernandez-Enriquez, O., Alvarez, R., Morelli, F., Fernando Bastida Milián, Camacho, D., and Menendez, J.

Subjects
Dose-Response Relationship, Drug, Cuba, Plant Weeds, Agriculture, Fabaceae
Abstract

Dichrostachys cinerea is a thorny, acacia-like, fast-growing woody bush which invades fields, wasteland, road sides and other disturbed areas. This gregarious species has become a very aggressive invasive weed in Cuba, where no native predators or pathogens are found. It often encroaches in fallows, overgrazed areas and mismanaged veld. D. cinerea is a very difficult weed to eliminate because of its active suckering, and is liable to produce dense thickets which are quite impenetrable on account of the density and abundance of its long, stiff, sharp thorns. In the Valle de los Ingenios area (Cuba Central), the tree is unchecked and forms veritable forests in areas on which cane growing has been discontinued. Physical management by cutting and burning the plants is not a very efficient control method, since the seeds survive in the soil, and they grow very fast. Therefore, chemical methods via the use of herbicides are often necessary to eradicate this weed. A preliminary study using glyphosate and auxin-like herbicides (2,4-D + picloram, MCPA, and MCPA + 2,4-D) plus adjuvants has been carried out in order to elucidate the best mixtures rendering maximum weed control with minimum herbicide rate and environmental stress. None of the herbicides used except glyphosate and 2,4-D + picloram showed acceptable mortality rates (75-80%) at the recommended doses tested. In the failed herbicide treatments, only the use of double herbicide rates succeeded in controlling marabou. The herbicide mixture of 2,4-D + picloram formulated with either a non-ionic surfactant or a mixture of fatty acid esters was the best option to control D. cinerea in terms of maximum effectiveness and minimum environmental stress, as the reduction in active ingredients applied to the environment was x3 in these two adjuvant-amended formulations compared to 2,4-D + picloram alone.

Published
2013

108. Anti-inflammatory peptides: an update and future perspective

Author

SANTAGADA V, METAFORA S, CALIENDO G, MAFFIA P, MORELLI F, DE ROSA R, DE MARIA G, CARTENI' M., IALENTI, ARMANDO, Cartenì M, Santagada, V, Ialenti, Armando, Metafora, S, Caliendo, G, Maffia, P, Morelli, F, DE ROSA, R, DE MARIA, G, and Carteni', M.

Published
2002

109. Phosphorylation of seminal vesicle protein IV on Ser58 enhances its peroxidase-stimulating activity

Author

METAFORA V, FRANCO P, MASSA O, MORELLI F, FERRANTI P, MAMONE G, MALORNI A, STOPPELLI MP, METAFORA S., STIUSO, Paola, Metafora, Mv, Franco, P, Massa, O, Morelli, F, Stiuso, P, Ferranti, Pasquale, Mamone, G, Malorni, A, Stoppelli, P, Metafora, S., Metafora, V, Stiuso, Paola, Ferranti, P, and Stoppelli, Mp

Subjects
Male, Glutathione Peroxidase, Spectrometry, Mass, Electrospray Ionization, Molecular Sequence Data, Seminal Plasma Proteins, Proteins, Seminal Vesicles, Cyclic AMP-Dependent Protein Kinases, Peptide Fragments, Rats, Inbred F344, Rats, Kinetics, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Serine, Animals, Tetradecanoylphorbol Acetate, Amino Acid Sequence, Phosphorylation, Rats, Wistar, Chromatography, High Pressure Liquid, Horseradish Peroxidase, Protein Kinase C
Abstract

In this study we show that SV-IV, a major immunomodulatory, anti-inflammatory, and sperm immunoprotective protein secreted from the rat seminal vesicle epithelium, acts in vitro as a substrate of protein kinase C (PKC) competing efficiently with H1 histone, a very well known PKC substrate. Electrospray mass spectrometry (ES-MS) analysis demonstrated that approximately 10% of the native SV-IV molecules were phosphorylated by PKC and that such a modification involved only a single serine residue (Ser58) out of the 22 occurring in the protein. Interestingly, this modification produced a substantial enhancement (approximately 50%) of the native SV-IV's ability to stimulate the activity of both horseradish peroxidase (POD) and selenium-dependent glutathione peroxidase (GPX), an enzyme that is known to protect the mammalian spermatozoa from oxidative stress and loss of motility in the female genital tract following ejaculation. In contrast, the phosphorylation of SV-IV on Ser58 did not produce any effect on the anti-inflammatory properties of SV-IV, as measured by its ability to inhibit the phospholipase A2.

Published
2001

110. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

Author

Cognetti, F, Ruggeri, Em, Felici, A, Gallucci, M, Muto, G, Pollera, Cf, Massidda, B, Rubagotti, A, Giannarelli, D, Boccardo, F, Cantiani, R, Adamo, Vincenzo, Aglietta, M, Bertetto, O, Cetto, Gl, Orlandini, P, Ferrazzi, E, Nardi, M, Manzione, L, Porcile, G, Lentini, M, Breda, E, Gamucci, T, Tummarello, D, Dogliotti, L, Tumolo, S, Motta, M, Lo Russo, V, De Grande, G, Sacco, C, Gaion, F, Lavarello, A, Nuzzo, A, Clerico, M, Aragona, C, Gernone, A, Morelli, F, Cupini, Mattioli, R, Marra, A, Antimi, M, Silingardi, V, Labianca, R, Martoni, A, Bortolussi, V, Luoni, M, Rosabian, A, Di Vito, F, Catalano, G, and Gebbia, N.

Subjects
bladder cancer adjuvant chemotherapy phase III trial
Published
2012

111. The leader peptide of a human rec. MnSOD as molecular carrier which delivers high amount of cisplatin into tumor cells inducing a fast apoptosis in vitro

Author

Borrelli A, Schiattarella A, Mancini R, Morelli F, Capasso C, De Luca V, Gori E, Mancini A. Borrelli A, and Mancini A.

Abstract

The leader peptide of a recombinant MnSOD (rMnSOD-Lp) constitutes the carrier that allows rMnSOD to penetrate tumor cells. A synthetic preparation of rMnSOD-Lp was (68)Ga labelled (rMnSOD-Lp-(68)Ga) and injected into animals bearing spontaneous mammary cancers, followed by PET examinations which demonstrated unambiguously the tumor sites in all the animals, suggesting that if rMnSOD-Lp was able to transport the radioisotope into tumor cells, it would also be able to deliver cytotoxic molecules. The rMnSOD-Lp was therefore conjugated to cisplatin (rMnSOD-Lp-CC) and added to cultured tumor cells. Equal concentrations of cisplatin were used for the tests. After treating the ovarian cancer cells with 11.1 mug of cisplatin alone, analysis by atomic absorbance spectrophotometry was able to detect only 6 ng of platinum, whereas when the same cells were treated with the same amount of cisplatin conjugated to leader peptide rMnSOD, 387 ng of platinum were detected, i.e. an amount 80 times greater. Only the tumor cells died following treatment with rMnSOD-Lp-CC; molecular analysis revealed that its addition generated an increasing expression of Erk-2 and Bax products which could be inhibited only by a selective MAP/ERK kinase inhibitor (PD98059), revealing that rMnSOD-Lp-CC has an apoptotic function, exactly as occurs when using the cisplatin alone. Data are statistically significant and indicate that by using rMnSOD-Lp-CC, the cisplatin can be transformed from an agent with antireplicative activity into a specific and selective antitumor molecule, increasing its therapeutic index. We think that rMnSOD-Lp-CC deserves to be considered as a new antitumor agent. (c) 2010 UICC

Published
2011

113. 2627 Characteristics and treatments patterns of patients with an advanced or metastatic urothelial carcinoma (UC) after failure of a platinum-based chemotherapy (CT): Results of the European observational study EPICURE

Author

Houede, N., primary, Locker, G.J., additional, Lucas, C., additional, Parra, H.J. Soto, additional, Basso, U., additional, Spaeth, D., additional, Tambaro, R., additional, Basterretxea, L., additional, Morelli, F., additional, Theodore, C., additional, Lusuardi, L., additional, Lainez, N., additional, Guillot, A., additional, Tonini, G., additional, Burillon, J.P., additional, and Del Muro, X. Garcia, additional

Published
2015
Full Text
View/download PDF

114. Exploring the role of MKK7 in excitotoxicity and cerebral ischemia: a novel pharmacological strategy against brain injury

Author

Vercelli, A, primary, Biggi, S, additional, Sclip, A, additional, Repetto, I E, additional, Cimini, S, additional, Falleroni, F, additional, Tomasi, S, additional, Monti, R, additional, Tonna, N, additional, Morelli, F, additional, Grande, V, additional, Stravalaci, M, additional, Biasini, E, additional, Marin, O, additional, Bianco, F, additional, di Marino, D, additional, and Borsello, T, additional

Published
2015
Full Text
View/download PDF

116. OC-006: Concomitant treatment (CRT or cetuximab/RT) with or without induction TPF in Locally Advanced head and neck

Author

Ghi, Cancer M.G., primary, Paccagnella, A., additional, Ferrari, D., additional, Foa, P., additional, Cossu Rocca, M., additional, Verri, E., additional, Morelli, F., additional, Azzarello, G., additional, D'Ambrosio, C., additional, Casanova, C., additional, Guaraldi, M., additional, Massa, E., additional, Rossetto, C., additional, Bonetti, A., additional, Siena, S., additional, Frattegiani, A., additional, Koussis, H., additional, Pieri, G., additional, Gava, A., additional, and Floriani, I., additional

Published
2015
Full Text
View/download PDF

118. Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study

Author

DE RAI, P, Zerbi, A, Castoldi, L, Bassi, C, Frulloni, L, Uomo, G, Gabbrielli, A, Pezzilli, R, Cavallini, G, DI CARLO, V, PROINF AISP PROGETTO INFORMATIZZATO PANCREATITE ACUTA, ASSOCIAZIONE ITALIANA PER LO STUDIO DEL PANCREAS COMPUTERIZED PROJECT ON ACUTE PANCREATITIS, COLLABORATORS AGUGIARO S, ITALIAN ASSOCIATION FOR THE STUDY OF THE PANCREAS STUDY G. R. O. U. P., Turri, L, Bartoli, A, Barberini, F, Cavazzoni, G, Bartolo, F, Papa, Dd, Bassi, Nicolo', Massani, M, Benedetti, A, Macarri, G, Piergallini, L, Briani, G, Bartolasi, L, Bugnano, L, Buonanno, Gm, Esposito, C, Cordovana, A, Cavina, E, Seccia, M, Lippolis, P, Musco, B, Barletta, M, Chilovi, E, DE GUELFI, A, Chirletti, P, Caronna, R, Scozzafava, S, Cardi, M, Cirino, E, Buffone, A, Colangelo, E, Caracino, V, Cortese, F, Casentini, A, Costamagna, G, Trincali, A, Curzio, M, Clivio, S, Segato, S, D'Alessandro, A, Ambrosiani, V, D'Ambrosio, B, Chiodo, C, Dicillo, M, Reale, L, Grandolfo, A, Fabbrucci, P, Bruscino, A, Mugnaini, P, Ferrarese, S, Ugenti, I, Forte, Gb, Rocco, P, Franzãˆ, A, Bertelãˆ, A, Sereni, G, Friedman, D, Mariani, L, Morelli, F, Gai, V, Antro, C, Garcea, D, Gardini, A, Lucci, E, Giulianotti, Pc, Sbrana, F, Balestracci, T, Giulini, Sm, Pellizzari, A, Ronconi, M, Cimaschi, S, Grassini, M, Lacignola, S, Calandro, L, Mazzitelli, L, Costarella, Sm, Egidio, A, Teggia, Pm, Stefano, E, Cassini, P, Modica, G, Lupo, F, Giraci, G, Mosca, F, DEL CHIARO, M, Mosella, G, Benassai, G, Nanni, M, D'Aristotile, A, Negro, P, Pirazzoli, A, Rabitti, Pg, Romano, C, Gerardi, G, Troianello, B, Russello, D, DI STEFANO, A, Avelli, S, Salval, N, Bellini, N, Scalon, P, Staudacher, C, Parolini, D, Strazzabosco, M, Signorelli, S, Tedeschi, U, Testoni, Pa, Masci, E, Mariani, A, Torelli, E, Garcea, Mr, Lombardi, V, Lecconi, L, Valeri, L, Presenti, L, Alessio, F, Ventrucci, M, Virzi, S, and Cipolla, A.

Published
2010

119. P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentre retrospective study

Author

Caffo, O., primary, De Giorgi, U., additional, Fratino, L., additional, Alesini, D., additional, Basso, U., additional, Facchini, G., additional, Gasparro, D., additional, Ortega, C., additional, Tucci, M., additional, Verderame, F., additional, Campadelli, E., additional, Re, G. Lo, additional, Procopio, G., additional, Sabbatini, R., additional, Donini, M., additional, Morelli, F., additional, Sartori, D., additional, Zucali, P., additional, Conteduca, V., additional, Maines, F., additional, and Galligioni, E., additional

Published
2014
Full Text
View/download PDF

121. The immunomodulatory protein SV-IV protects serum-deprived cells againstapoptosis but not against G0/G1 arrest: possible implications for the survival ofimplanting embryo

Author

Morelli, F, Peluso, G, Petillo, O, Giannattasio, A, Filosa, S, Motta, Cm, Tammaro, S, Zatterale, A, Calzone, R, Budillon, A, Cartenì, M, DE MARIA, S, Costanza, Mr, Nigro, A, Petrazzuolo, M, Buommino, E, Rizzo, M, Capasso, G, Baiano, S, Moscatiello, F, Ravagnan, G, Fuggetta, Mp, Tajana, Gianfranco, Stiuso, P, Metafora, Bm, Metafora, V, and Metafora, S.

Published
2007

124. Risk factors and predictive indexes of early graft failure in liver transplantation

Author

Marino IR, Starzl TE, Aldrighetti L, Doria C, Morelli F, Gayowski TJP, Madariaga JR, Doyle HR, Marino, Ir, Starzl, Te, Aldrighetti, L, Doria, C, Morelli, F, Gayowski, Tjp, Madariaga, Jr, and Doyle, Hr

Subjects
Adult, Graft Rejection, Male, Time Factors, Graft Survival, Age Factors, Middle Aged, Tissue Donors, Liver Transplantation, Treatment Outcome, Predictive Value of Tests, Risk Factors, Case-Control Studies, Multivariate Analysis, Humans, Female, Retrospective Studies
Abstract

A retrospective analysis of 462 consecutive liver transplantations has been carried out, These were divided into two groups, according to whether they failed within 90 days (Group I) or survived longer than 90 days (Group II). Twenty-five donor and recipient variables were analyzed, In the univariate analysis, the only donor variable that was significantly different between the two groups was age (45.3 +/- 16.9 years in Group I vs 37.9 +/- 15.4 years in Group II, p < 0.001), There were five recipient variables significantly associated with early graft failure: history of previous liver transplantations (p < 0.0001), United Network for Organ Sharing 4 status (p = 0.003), primary diagnosis (p = 0.001), preoperative serum creatinine (1.97 +/- 1.5 mg/dL, in Group I vs 1.46 +/- 1.2 mg/dL, in Group II, p = 0.005), and preoperative total serum bilirubin (13.5 +/- 14.4 mg/dL in Group I vs 8.4 +/- 11.4 mg/dL in Group II, p = 0.003), In the multivariate analysis, only three variables were independently associated with outcome: donor age greater than 45 years, abnormal (> 1.5 mg/dL) recipient preoperative creatinine, and a history of previous liver transplantation.

Published
1996

126. Use of digitalis in the treatment of heart failure: data from the Italian Network on Congestive Heart Failure (IN-CHF)

Author

Camerini, A, Griffo, R, Aspromonte, N, Ingrilli', F, Lucci, D, Naccarella, F, Maggioni, Ap, IN-CHF INVESTIGATORS- Piemonte Borgomanero (M. Zanetta, A. M. Paino), Casale Monferrato (M. Ivaldi, A. Giusti), Uslenghi, Cuneo (E., Milanese, U., Deorsola), A., Greco Lucchina, Orbassano (P., Pozzi, R., Rabajoli), F., Veruno (P. Giannuzzi, E. Bosimini), Valle d’Aosta Aosta (M. De Marchi, G. Begliuomini), Richichi, Lombardia Belgioioso (I., Ferrari, A., Barzizza), F., Bergamo Riabilitazione Cardiologica (A. Gavazzi, F. Dadda), Bergamo U. O. Cardiologia Cardiovascolare (A. Gavazzi, A. Fontana), Brescia (C. Rusconi, P. Faggiano), Cogo, Cassano D’Adda (R., Castiglioni, G., Gibelli), G., Chiari (F. Bortolini, A. L. Turelli), Como (G. Ferrari, R. Jemoli), Pirelli, Cremona (S., Bianchi, C., Emanuelli), C., De Martini), Desio (M., Erba (G. Maggi, D. Agnelli), Ferrara), Esine (E., Rovelli, Garbagnate Milanese (G., Lureti, G., Cazzani), E., Giordano, Gussago (A., Zanelli, E., Domenighini), D., Legnano (S. De Servi, C. Castelli), Mariano Comense (G. Bellati, E. Moroni), Milano Fondazione Don Carlo Gnocchi IRCCS (M. Ferratini, E. Gara), Malliani, Milano Sacco (A., Muzzupappa, S., Turiel, M., Guzzetti, S., Cappiello), E., Milano Niguarda (S. Klugmann, F. Recalcati), Milano Pio Albergo Trivulzio (S. Corallo, D. Valenti), Cobelli), Montescano (F., Monza (A. Grieco, A. Vincenzi), Schweiger, Passirana-Rho (C., Rusconi, F., Palvarini), M., Ferrari, Pavia IIAARR S. Margherita (E., Carbone), M., Tavazzi, Pavia IRCCS Policlinico San Matteo (L., Campana, C., Serio), A., Croce, Saronno (A., Nassiacos, D., Meloni), S., Seriate (P. Giani, T. Nicoli), Sondalo (G. Occhi, P. Bandini), Sondrio (S. Giustiniani, M. Moizi), Tradate Fondazione S. Maugeri (R. Pedretti, M. Paolucci), Onofri, Tradate Ospedale di Circolo Galmarini (M., Amati, L., Ravetta), M., Venco, Varese Medicina Interna Azienda Ospedaliera e Universitaria (A., Bertolini, A., Saggiorato), P., Salerno Uriarte, Varese U. O. Cardiologia Azienda Ospedaliera e Universitaria (J., Morandi, F., Provasoli), S., Vizzolo Predabissi (M. Lombardo, P. Quorso), P. A. Trento Rovereto Cardiologia Ospedale Civile (G. Vergara, A. Ferro), Rovereto Medicina Ospedale Civile (M. Mattarei, C. Pedrolli), Catania, Veneto Belluno (G., Tarantini, L., Russo), P., Castelfranco Veneto (L. Celegon, G. Candelpergher), Conegliano Veneto (P. Delise, C. Marcon), Guarnerio, Feltre (M., De Cian, F., Agnoli), A., Montebelluna (G. Neri, M. G. Stefanini), Iliceto, Padova (S., Boffa, G. M., Tiso), E., Pieve di Cadore (J. Dalle Mule, A. Stefania), San Bonifacio (R. Rossi, E. Carbonieri), Treviso (P. Stritoni, G. Renosto), Fontanelli, Vicenza (A., Ottani, F., Varotto), L., Perini), Villafranca (G., Friuli Venezia Giulia Gorizia (D. Igidbashian, G. Giuliano), Monfalcone (T. Morgera, E. Barducci), San Vito al Tagliamento (M. Carone, G. Pascottini), Fioretti, Udine A. O. S. Maria della Misericordia (P., Albanese, M. C., Fresco), C., Udine Casa di Cura Città di Udine (P. Venturini, F. Picco), Liguria Arenzano (R. Griffo, A. Camerini), Chierchia, Genova Ospedali Civili (S., Mazzantini, S., Torre), F., Spirito, Genova Ospedali Galliera (P., Derchi, G., Delfino), L., Genova-Sestri Ponente (S. Domenicucci, L. Pizzorno), Località S. Caterina-Sarzana (G. Filorizzo, D. Bertoli), Rapallo (G. Gigli, S. Orlandi), Gentile), Sestri Levante (A., Emilia Romagna Bentivoglio (G. Di Pasquale, R. Vandelli), Bologna Cardiologia Tiarini-Corticella (F. Naccarella, M. Gatti), Forlì (F. Rusticali, G. Morgagni), Modena Medicina d’Urgenza Ospedale Civile S. Agostino (S. Zucchelli, M. Pradelli), Modena U. O. Cardiologia Ospedale Civile S. Agostino (G. R. Zennaro, G. Alfano), Modena, Modena Ospedale Policlinico (M. G., Reggianini, L., Coppi), F., Parma (D. Ardissino, W. Serra), Piacenza (A. Capucci, F. Passerini), Riccione (L. Rusconi, P. Del Corso), Piovaccari, Rimini (G., Bologna, F., Caccamo), L., Gambarati), Scandiano (G., Bernardi, Toscana Castelnuovo Garfagnana (D., Mariani, P. R., Volterrani), C., Cosmi), Cortona (F., Empoli (V. Mazzoni, F. Venturi), Firenze Divisione di Cardiologia A. O. Careggi (D. Antoniucci, G. Moschi), Zuppiroli, Firenze U. O. Cardiologia 3 A. O. Careggi (A., Pieri, F., Beligni), C., Firenze U. O. Cardiologia 2 A. O. Careggi (M. Ciaccheri, G. Castelli), Santoro, Firenze Nuovo Ospedale San Giovanni di Dio (G. M., Minneci, C., Sulla), A., Firenze P. O. di Camerata (F. Marchi, G. Zambaldi), Fucecchio (A. Zipoli, A. Geri Brandinelli), Grosseto (S. Severi, G. Miracapillo), Pesola, Lido di Camaiore (A., Comella, A., Magnacca), M., Lucca (E. Nannini, A. Boni), Mantini, Montevarchi (G., Bongini, M., Palmerini), L., Vergoni, Pescia (W., Italiani, G., Di Marco), S., Pisa A. O. Pisana (M. De Tommasi, A. M. Paci), Pontedera (G. Tartarini, B. Reisenhofer), Umbria Città di Castello (M. Cocchieri, D. Severini), Foligno (L. Meniconi, U. Gasperini), Ambrosio, Perugia (G., Alunni, G., Murrone), A., Spoleto (G. Maragoni, G. Bardelli), Mocchegiani, Marche Ancona Centro Cardiologia Ambulatoriale G. M. Lancisi (R., Pasetti, L., Budini), A., Ancona Divisione di Cardiologia G. M. Lancisi (G. Perna, D. Gabrielli), Russo, Ancona Geriatrico Sestilli-INRCA IRCCS (P., Testarmata, P., Antonicelli), R., Camerino (R. Amici, B. Coderoni), Lazio Albano Laziale (G. Ruggeri, P. Midi), Frascati (G. Giorgi, F. Comito), Frosinone (G. Faticanti, F. Qualandri), Grottaferrata (D. Galileo Faroni, C. Romaniello), Roma INRCA (F. Leggio, D. del Sindaco), Majid Tamiz, Roma C. Forlanini (A., Avallone, A., Suglia), F., Roma Cristo Re (V. Baldo, E. Baldo), Roma I U. O. Cardiologia San Camillo (E. Giovannini, G. Pulignano), Roma II Divisione di Cardiologia con UTIC San Camillo (S. F. Vajola, E. Picchio), Tanzi, Roma Serv. Centr. Cardiologia-PS Cardiologico San Camillo (P., Pozzar, F., Terranova), A., Santini, Roma San Filippo Neri (M., Ansalone, G., Magris), B., Boccanelli, Roma San Giovanni (A., Cacciatore, G., Bottero), G., Palamara, Roma Sandro Pertini (A., Valtorta, C., Salustri), A., Roma S. Andrea (M. Volpe, L. De Biase), Gaspardone, Roma S. Eugenio (A., Amaddeo, F., Barbato), G., Ceci, Roma Santo Spirito (V., Aspromonte, N., Chiera), A., Scabbia, Viterbo (E. V., Pontillo, D., Castellani), R., Abruzzo Popoli (C. Frattaroli, A. Mariani), De Simone, Vasto (G., Levantesi, G., Di Marco), G., Molise Larino Medicina Generale-U. O. Geriatria (F. Porfilio, A. Pasquale Potena), Staniscia, Termoli (D., Colonna, N., Montano), A., Mininni, Campania Napoli Divisione di Cardiologia A. O. V. Monaldi (N., Miceli, D., Scherillo), M., Napoli I Divisione Med-Centro Diagnosi e Cura SCC A. O. V. Monaldi (P. Sensale, O. Maiolica), Napoli Medicina Incurabili (M. Visconti, A. Costa), Napoli Cardiologia San Gennaro (P. Capogrosso, A. Somelli), Vergara, Nola U. O. Cardiologia e UTIC P. O. Maria della Pietà (G., Napolitano, F., Provvisiero), P., Oliveto Citra (G. D’Angelo, P. Bottiglieri), Puglia Bari (G. Antonelli, N. Ciriello), Ignone, Brindisi (G., Angelini, E., Andriulo), C., Casarano (G. Pettinati, F. De Santis), Francavilla Fontana (V. Cito, F. Cocco), Galatina (F. Daniele, A. Zecca), Gallipoli (F. Cavalieri, C. Picani), Lecce Vito Fazzi (F. Magliari, A. De Giorgi), Santoro), Mesagne (V., San Pietro Vernotico (S. Pede, A. Renna), Scorrano (E. De Lorenzi, O. De Donno), Baldi, Taranto S. S. Annunziata (N., Polimeni, G., Russo), V. A., Tricase (A. Galati, R. Mangia), Basilicata Policoro (B. D’Alessandro, L. Truncellito), Calabria Belvedere Marittimo (F. P. Cariello, F. Rosselli), Catanzaro U. O. Cardiologia Policlinico (G. Borrello, M. Affinita), Catanzaro U. O. Malattie Cardiovascolari Policlinico (F. Perticone, C. Cloro), Sollazzo, Cetraro (G., Matta, M., Lopresti), Venneri, Cosenza Cardiologia Annunziata (N., Misuraca, G., Caporale), R., Cosenza Medicina Annunziata (A. Noto, P. Chiappetta), Tassone), Reggio Calabria E. Morelli (F., Salituri), Rossano (S., Iannopollo, Siderno (M., Errigo, C., Marando), G., Trebisacce (L. Donnangelo, G. Meringolo), Canonico), Sicilia Avola (G., Carini, Catania Cannizzaro (V., Coco, R., Franco), M., Catania Cardiochirurgia Ferrarotto (M. Abbate, G. Leonardi), Messina Papardo (R. Grassi, G. Di Tano), Consolo), Messina Piemonte (G., Coglitore, Messina (S., Cento, D., De Gregorio), C., Palermo Casa del Sole Lanza di Trabia (V. Sperandeo, M. Mongiovì), Palermo Buccheri La Ferla FBF (A. Castello, A. M. Schillaci), Palermo Civico e Benfratelli (E. D’Antonio, U. Mirto), Di Pasquale), Palermo G. F. Ingrassia (P., Palermo V. Cervello (A. Canonico, M. Floresta), Battaglia, Palermo P. O. Villa Sofia (A., Ingrillì, F., Cirrincione), V., Piazza Armerina M. Chiello (B. Aloisi, A. Cavallaro), Braschi, Trapani (G. B., Ledda, G., Rizzo), C., Sanna, Sardegna Cagliari San Michele Brotzu (A., Porcu, M., Salis), S., Lai, Cagliari SS. Trinità (C., Pili, G., Piras), S., Iglesias (E. Spiga, G. Pes), Nuoro (G. Mureddu, I. Maoddi), and Sassari SS. Annunziata (P. Terrosu, F. Uras).

Subjects
Adult, Heart Failure, Male, Dose-Response Relationship, Drug, Digitalis Glycosides, Middle Aged, Prognosis, Risk Assessment, Severity of Illness Index, Survival Analysis, Drug Administration Schedule, Drug Utilization, Treatment Outcome, Italy, Atrial Fibrillation, Heart Function Tests, Multivariate Analysis, Ambulatory Care, Confidence Intervals, Odds Ratio, Humans, Female, Registries, Aged, Retrospective Studies
Abstract

Since the large multicenter DIG trial has shown no effects of digitalis on the all-cause mortality of patients with chronic heart failure (HF), the broad prescription of this drug in patients with HF appears to be at the very least, questionable. The aims of this study were: to analyze prescription patterns of digitalis, from 1995 to 2000, in a large group of outpatients with HF; to analyze the independent predictors of digitalis prescription and to evaluate the impact of the results of the DIG trial on the prescription rate of this drug.From 1995 to 2000, 11 070 HF outpatients (mean age 64 +/- 12 years, ejection fraction 35 +/- 12%) were enrolled in a large Italian database.Out of 11 070 patients, 7198 (65%) were treated with digitalis. At multivariate analysis, the following variables were independently associated with digitalis prescription; atrial fibrillation (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.9-3.8), ejection fraction30% (OR 1.7, 95% CI 1.5-1.9), NYHA class III-IV vs II-III (OR 1.3, 95% CI 1.2-1.5), admission for HF during the previous year (OR 1.4, 95% CI 1.2-1.5). After the publication of the DIG trial, there was a significant reduction in the rate of digitalis prescription: the percentage of patients taking digitalis fell from 68% in 1996-1997 to 61% in 1998-1999 (p0.001).Over 60% of Italian outpatients with HF were treated with digitalis; as expected, patients with a low ejection fraction, atrial fibrillation and in a more advanced stage of HF are more likely to receive this drug. Finally, after the publication of the DIG trial, the rate of digitalis prescription significantly decreased.

Published
2004

127. Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience

Author

Caffo, O., primary, De Giorgi, U., additional, Fratino, L., additional, Facchini, G., additional, Basso, U., additional, Alesini, D., additional, Gasparro, D., additional, Ortega, C., additional, Tucci, M., additional, Verderame, F., additional, Campadelli, E., additional, Re, G. Lo, additional, Sabbatini, R., additional, Donini, M., additional, Procopio, G., additional, Sartori, D., additional, Zucali, P.A., additional, Carrozza, F., additional, D'Angelo, A., additional, and Morelli, F., additional

Published
2014
Full Text
View/download PDF

132. Effect of protein SV-IV on experimental Salmonella enterica serovar Typhimurium infection in mice

Author

Romano-Carratelli C., Bentivoglio C., Nuzzo I, Benedetto N., Buommino E., Cozzolino A., Carteni M., Morelli F., Costanza M.R., Metafora B., Metafora V., and Metafora S.

Abstract

Seminal vesicle protein IV (SV-IV) is a secretory anti-inflammatory, procoagulant, and immunomodulatory protein produced in large amounts by the seminal vesicle epithelium of the rat under the strict transcriptional control of androgen. In particular, this protein was shown to possess the ability to markedly inhibit in vivo the humoral and cell-mediated immune responses of mice to nonbacterial cellular antigens (sheep erythrocytes and spermatozoa). We report data that demonstrate that in mice treated with SV-IV and infected with Salmonella enterica serovar Typhimurium, SV-IV is able to downregulate some important immunological and biochemical parameters that serovar Typhimurium normally upregulates in these animals. This event did not correlate with a lower bacterial burden but was associated with a markedly increased one (300%). Furthermore, the treatment of mice with SV-IV alone also produced a significant increase in the rate of mortality among serovar Typhimurium-infected animals. The mechanism underlying these phenomena was investigated, and the strong immunosuppression produced by SV-IV in serovar Typhimurium-infected mice was suggested to be the basis for the increased rate of mortality. The SV-IV-mediated immunosuppression was characterized by a decrease in the humoral and cell-mediated immune responses, altered lymphocyte-macrophage interaction, downregulation of cytokine and inducible nitric oxide synthase gene expression, inhibition of macrophage phagocytosis and intracellular killing activities, and absence of apoptosis in the splenocyte population of SV-IV- and serovar Typhimurium-treated mice. The immunosuppressive activity of SV-IV was specific and was not due to aspecific cytotoxic effects. SV-IV-specific receptors (K(d) = 10(-8) M) occurring on the macrophage and lymphocyte plasma membranes may be involved in the molecular mechanism underlying the SV-IV-mediated immunosuppression. Some results obtained by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay also revealed a functional impairment of mitochondria (a decrease in mitochondrial dehydrogenase activity), thus indicating the possible implication of these organelles in the immunosuppressive process.

Published
2002

134. Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP)Gln16 residue modulates VIP/PACAP receptor activity

Author

De Maria S, Metafora S, Metafora V, Morelli F, Robberecht P, Waelbroeck M, Stiuso P, De Rosa A, Cozzolino A, Esposito C, Facchiano A, and Carteni M.

Subjects
hormones, hormone substitutes, and hormone antagonists
Abstract

Previous data showing an increase of receptor binding activity of [R16]VIP, a vasoactive intestinal peptide (VIP) structural analogue containing arginine at the position 16 of its amino acid sequence, have pointed out the importance of a positive charge at this site. Here, the functional characterization of three VIP polyaminated adducts (VIPDap, VIPSpd, and VIPSpm), obtained by a transglutaminase-catalysed reaction between the VIP Gln16 residue and 1,3-diaminopropane (Dap), spermidine (Spd), or spermine (Spm), is reported. Appropriate binding assays and adenylate cyclase enzymatic determinations have shown that these VIP adducts act as structural VIP agonists, both in vitro and in vivo. In particular, their IC50 and EC50 values of human and rat VIP/pituitary adenylate cyclase activating peptide (PACAP)1 and VIP/PACAP2 receptors indicate that VIPDap is a VIP agonist, with an affinity and a potency higher than that of VIP, while VIPSpd and VIPSpm are also agonists but with affinities lower than that of VIP. These findings suggest that the difference in adduct agonist activity reflects the differences in the positive charge and carbon chain length of the polyamine covalently linked with the VIP Gln16 residue. In addition, the data obtained strongly suggest that the length of polyamine carbon chain could be critical for the interaction of the agonist with its receptor, even though possible hydrophobic interaction cannot be ruled out. In vivo experiments on murine J774 macrophage cell cultures have shown the ability of these compounds to stimulate the inducible nitric oxide synthase activity at the transcriptional level.

Published
2002

142. Habitat structure, breeding stage and sex affect hunting success of breeding Red-backed Shrike ( Lanius collurio ).

Author

Morelli, F., Mróz, E., Pruscini, F., Santolini, R., Goławski, A., and Tryjanowski, P.

Subjects
*RED-backed shrike, *BIRD habitats, *BIRD breeding, *FORAGING behavior, *BIRDS of prey
Abstract

Perch-sites are a necessary component for birds that employ a sit-and-wait foraging strategy, like Red-backed Shrikes (Lanius collurio). However, little is known about the influence of perch characteristics and its relation to the foraging substrate, elements that influence prey-capture success. This study was conducted in parallel in Italy and Poland and is based on > 5000 min of behavioural observations in the field. Our results show that perch type and foraging substrate characteristics affect the hunting behaviour of the Red-backed Shrike. The species utilises for its hunting activities mainly human-related structures. The foraging substrates most frequently used were ground (surface in cultivated, uncultivated, grassland and roads) and air; and secondarily the vegetation (mainly foliage of shrubs or trees). The average hunting success rate was 60%, but there were differences between Italy and Poland. Hunting success was highest for a combination of perch types (shrubs and foraging substrate on ground), and also from power lines in order to capture prey on roads. Although roads were less frequently used than other foraging substrates, they offered the highest hunting success. We found no effects of sex, period of day or weather conditions on hunting success. However, success rate increased during the last stages of the breeding season, i.e. during hatching and feeding of nestlings. The wide variety of preys and foraging substrates recorded in this study are typical for an opportunistic bird species. Open, warm spaces appear to constitute prime foraging habitat for the species, and some human-related structures as barbed wires, power lines and marginal hedges offer preferred support as perch-sites. Then, the presence and combination of some of these structures can help to improve the success rate of hunting attempts of Red-backed Shrikes. Our results can constitute a useful tool for ecological planning and enhance the conservation of this typical species of agricultural landscapes. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

144. Concomitant Chemoradiotherapy (CT/RT) or CETUXIMAB/RT (CET/RT) with or Without Induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) in Locally Advanced Head and Neck Cancer (LASCCHN). Preliminary Toxicity Results of a Randomized, 2x2 Factorial, Phase II-III Study. (NCT01086826)

Author

Ghi, M.G., primary, Paccagnella, A., additional, Ferrari, D., additional, Rocca, M. Cossu, additional, Verri, E., additional, Morelli, F., additional, Azzarello, G., additional, D'Ambrosio, C., additional, Casanova, C., additional, and Floriani, I.C., additional

Published
2012
Full Text
View/download PDF

148. RF properties of a X-band hybrid photoinjector

Author

Spataro, B., primary, Valloni, A., additional, Alesini, D., additional, Biancacci, N., additional, Faillace, L., additional, Ficcadenti, L., additional, Fukusawa, A., additional, Lancia, L., additional, Migliorati, M., additional, Morelli, F., additional, Mostacci, A., additional, O'Shea, B., additional, Palumbo, L., additional, Rosenzweig, J.B., additional, and Yakub, A., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results